Cargando…

The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies

Anti-programmed cell death protein 1 (PD-1) monoclonal antibody therapy is becoming a standard treatment for advanced melanoma that produces durable responses and prolonged survival, but the prognosis of patients with liver metastases is still unsatisfactory. Here, we analyzed five clinical studies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xuan, Ji, Qing, Yan, Xieqiao, Lian, Bin, Si, Lu, Chi, Zhihong, Sheng, Xinan, Kong, Yan, Mao, Lili, Bai, Xue, Tang, Bixia, Li, Siming, Zhou, Li, Cui, Chuanliang, Guo, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7552942/ https://www.ncbi.nlm.nih.gov/pubmed/33117684 http://dx.doi.org/10.3389/fonc.2020.546604

Ejemplares similares

Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials
por: Zhou, Li, et al.
Publicado: (2021)

Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy
por: Dai, Jie, et al.
Publicado: (2023)

Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy—Ad hoc Analyses of Pooled Data From Two Clinical Trials
por: Bai, Xue, et al.
Publicado: (2021)

Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy
por: Wang, Xuan, et al.
Publicado: (2020)

Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients
por: Wang, Xuan, et al.
Publicado: (2019)

Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies
por: Tian, Hui, et al.
Publicado: (2021)

Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study
por: Wei, Xiaoting, et al.
Publicado: (2019)

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis
por: Sheng, Xinan, et al.
Publicado: (2016)

A Functional Synonymous Variant in PDGFRA Is Associated with Better Survival in Acral Melanoma
por: Dai, Jie, et al.
Publicado: (2020)

A nomogram incorporating Ki67 to predict survival of acral melanoma
por: Du, Yu, et al.
Publicado: (2023)

Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure()
por: Cui, ChuanLiang, et al.
Publicado: (2018)

Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study
por: Zhou, Li, et al.
Publicado: (2022)

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
por: Tang, Bixia, et al.
Publicado: (2019)

Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G(4) Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial
por: Sheng, Xinan, et al.
Publicado: (2019)

OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study
por: Cui, ChuanLiang, et al.
Publicado: (2022)

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
por: Li, Siming, et al.
Publicado: (2022)

Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma
por: Tang, Lirui, et al.
Publicado: (2022)

Surgical Outcomes of Vaginal or Cervical Melanoma
por: Tian, Hui, et al.
Publicado: (2022)

Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma
por: Sheng, Xinan, et al.
Publicado: (2020)

Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial
por: Mao, Lili, et al.
Publicado: (2021)

HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population
por: Zhou, Li, et al.
Publicado: (2023)

The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma
por: Wei, Xiaoting, et al.
Publicado: (2020)

MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways
por: Ma, Meng, et al.
Publicado: (2019)

MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways: Erratum
por: Ma, Meng, et al.
Publicado: (2022)

Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases
por: Chi, Zhihong, et al.
Publicado: (2011)

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
por: Li, Siming, et al.
Publicado: (2014)

Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma
por: Cui, Chuanliang, et al.
Publicado: (2021)

Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon
por: Yu, Jiayi, et al.
Publicado: (2017)

PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis
por: Lin, Zhijuan, et al.
Publicado: (2016)

Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort
por: Bai, Xue, et al.
Publicado: (2021)

Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma
por: Dai, Jie, et al.
Publicado: (2017)

TERT copy gain predicts the outcome of high-dose interferon α-2b therapy in acral melanoma
por: Yu, Sifan, et al.
Publicado: (2018)

Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy
por: Yu, Huan, et al.
Publicado: (2017)

Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma
por: Wu, Xiaowen, et al.
Publicado: (2017)

Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study
por: Wei, Xiaoting, et al.
Publicado: (2022)

Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients
por: Yu, Jiayi, et al.
Publicado: (2018)

Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients
por: Yang, Wenchao, et al.
Publicado: (2022)

High G2 and S‐phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis
por: Xu, Tianxiao, et al.
Publicado: (2018)

Increased AURKA Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma
por: Yan, Junya, et al.
Publicado: (2018)

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy
por: Bai, Xue, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tpr65kl9etvg4lq36b93ojuat0